Crohn’s disease (CD) is one of the two main forms of inflammatory bowel disease, which affects an estimated three million Americans. CD is a chronic inflammatory condition of the gastrointestinal tract with no known cause, but the disease is associated with abnormalities of the immune system that could be triggered by a genetic predisposition, diet or other environmental factors. Symptoms of CD can vary but often include abdominal pain and tenderness, frequent diarrhea, rectal bleeding, weight loss and fever. There is currently no cure for CD.
Crohn’s disease is one of the two main forms of inflammatory bowel disease, which affects an estimated 3 million Americans.”
J&J approach to Crohn’s disease
Driven by a relentless focus on patient unmet need, we will redefine treatments for immune diseases by delivering transformational and accessible medicines and regimens to patients with autoimmune disease.
For more than 30 years, we have focused on developing novel, effective therapies, with a relentless focus on individuals living with chronic conditions who are experiencing persistent and debilitating symptoms due to digestive diseases.
Having pioneered the science focused on blocking an overabundance of interleukin-23 or IL-23, a cytokine, or protein, embedded in the body, which in excess amounts can open the door for inflammation, especially of the skin, joints and gut, we continue to explore innovation within this pathway. This is evidenced by clinical findings that have resulted in the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen. Looking forward, we are encouraged by promising results seen in Phase 2 studies of an investigational targeted oral peptide that selectively blocks the IL-23 receptor, as well as by a IL23/TNF combination therapy.
